Table 2.
Outcomes in the 7 included studies.
| Authors | Group of patients/study design | 90-day mortality | Number of infections |
|---|---|---|---|
| Spahr et al. (2008)13 | Patients randomly assigned to receive standard care + G-CSF | 1/13 (7.7) | 3/13 (23.1) |
| Patients randomly assigned to receive standard care + placebo | 0/11 (0) | 4/11 (36.4) | |
| Garg et al. (2012)17 | Patients randomly assigned to receive G-CSF | 7/23 (30.4)a | 3/23 (13.0) |
| Patients randomly assigned to receive placebo | 17/24 (70.8)a | 10/24 (41.6) | |
| Singh et al. (2014)36 | Patients randomly assigned to receive G-CSF + pentoxifylline | 5/23 (21.7) | 5/23 (21.7) |
| Patients randomly assigned to receive pentoxifylline | 18/23 (78.3) | 18/23 (78.3) | |
| Sharma et al. (2017)26 | Patients randomly assigned to receive G-CSF | 8/25 (32.0) | 6/25 (24.0) |
| Patients randomly assigned to receive placebo | 16/25 (64.0) | 17/25 (68) | |
| Singh et al. (2018)12 | Patients randomly assigned to receive G-CSF + pentoxifylline | 2/18 (11.1) | 2/18 (11.1) |
| Patients randomly assigned to receive pentoxifylline | 14/20 (70.0) | 14/20 (70.0) | |
| Shasthry et al. (2019)25 | Patients randomly assigned to receive G-CSF | 5/14 (35.7) | 4/14 (28.6) |
| Patients randomly assigned to receive placebo | 10/14 (71.4) | 10/14 (71.4) | |
| Engelmann et al. (2019)28 | Patients randomly assigned to receive G-CSF | 40/60 (66.7)b | 32/74 (43.2) |
| Patients randomly assigned to receive placebo | 27/52 (51.9)b | 34/78 (43.6) |
Data are presented as n/N (%).
G-CSF, granulocyte colony-stimulating factor.
a
Data for mortality at 60 days (data at 90 days not available).
b
Data for death or transplantation.